Economic Evaluations for Dementia Interventions

By Melike Belenli Gümüş

June 3, 2024

Introduction

Dementia presents a significant global healthcare challenge, impacting millions and straining resources. By 2050, the number of individuals affected is projected to reach 139 million. The economic burden is substantial, with costs expected to triple by 2030. Despite available treatments, access barriers persist. Economic evaluations for dementia interventions play a crucial role in resource allocation decisions, offering insights into intervention effectiveness.

Twenty-three studies with the majority being cost-utility analyses were comprised within the scope of a review. The included studies, which were conducted from February 2018 to August 2022, underwent quality assessment using the Philips checklist and the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 checklist. Various interventions were covered, including pharmacological, non-pharmacological, prevention, diagnostic, and integrated strategies. Markov transition models were commonly employed, with several interventions reported as cost-effective. However, the quality of reporting in the Methods and Results sections was suboptimal in most studies, highlighting areas for improvement in methodology and reporting standards.

Diversifying Intervention Approaches

While pharmacological treatments have been the focus, non-pharmacological strategies are also gaining recognition. However, research bias towards pharmacological interventions remains, highlighting the need for a balanced approach. Incorporating long-term outcomes and considering early-stage interventions are vital for comprehensive dementia management.

Global Disparities and Model Structures

Studies predominantly focus on high-income countries, indicating a need for broader geographical representation. Markov models are commonly used due to the chronic nature of dementia, with limited utilization of discrete-event simulation (DES) models. Transparent reporting of model assumptions and validation processes is essential for reliable results.

Addressing Methodological Gaps

Engaging stakeholders, including patients and caregivers, in model development enhances relevance and acceptance. While societal perspectives are crucial for comprehensive evaluations, their inclusion remains limited. Clear characterization of health states and consideration of multi-attribute measures are essential for accurate assessments.

Utility Measurement Challenges

Utility measurement methods lack detailed reporting, impacting the reliability of comparisons. The use of EQ-5D values is prevalent but may not capture the full spectrum of dementia-related health impacts. Incorporating condition-specific measures and distinguishing between self and proxy reports can enhance assessment accuracy.

Conclusions

This review provides valuable insights into model-based economic evaluations for dementia interventions, highlighting areas for improvement in methodology and reporting standards. By addressing existing gaps and methodological weaknesses, future studies can contribute significantly to optimizing dementia management strategies globally.

Reference url

Recent Posts

datopotamab deruxtecan approval
   

FDA Grants Datopotamab Deruxtecan Approval for HR-Positive Breast Cancer Treatment

💡 *What does the FDA’s latest approval mean for patients with advanced breast cancer?*
Datopotamab deruxtecan (Datroway) has just been approved for treating unresectable or metastatic HR-positive, HER2-negative breast cancer, offering new hope for patients who have already undergone multiple therapies. This breakthrough, stemming from the TROPION-Breast01 trial, showcases significant improvements in progression-free survival rates—a vital advancement in cancer care.

Curious about the implications of this treatment for both healthcare providers and patients? Dive into the full article to learn more!

#SyenzaNews #oncology #HealthcareInnovation

surrogate endpoints guidance
          

Surrogate Endpoints Guidance: New International Report Enhances HTA Practices

🔍 Are surrogate endpoints the key to shaping the future of health technology assessment?

A new report led by NICE reveals standardized guidance for using surrogate endpoints in health economic models, providing clarity and validation tools for HTA decisions. This collaborative effort across multiple global agencies aims to enhance predictions of long-term health benefits from short-term data.

Jump into the article to explore these impactful insights and learn how this guidance is set to improve health technology evaluations!

#SyenzaNews #HealthEconomics #HealthcareInnovation

cervical cancer prevention
    

Cervical Cancer Prevention Strategies: Insights from South African

🌍 Did you know South African women living with HIV face a significantly higher risk of cervical cancer?

Our latest article looks into the perspectives of women and their partners regarding innovative cervical cancer prevention strategies, including the acceptability of the intravaginal 5-fluorouracil (5FU) treatment. It highlights the critical role of education and counseling in improving screening uptake and treatment adherence.

Explore how we can enhance cervical health for vulnerable populations!

#SyenzaNews #globalhealth #oncology #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.